Kobo's Libra Colour and Elipsa 2E e-readers have dropped to some of their best prices
Kobo is discounting two of its best e-readers. The Kobo Elipsa 2E, a competitor to the Kindle Scribe, is available for an all-time low of $349.99 ($50 off) from Rakuten Kobo and Target. Meanwhile, the Kobo Libra Colour is available for $209.99 ($20 off) from Amazon, Target, and Rakuten Kobo. The sale runs through July 10th.
The Kobo Elipsa 2E is my top pick for taking notes while reading. Its spacious 10.3-inch display lets you write directly on ebook pages — whether in margins, between lines, or wherever inspiration strikes — giving you a natural, paper-like experience. While Amazon's Kindle Scribe supports on-page writing, its tools are far more limited; you can't freely annotate, circle text, or mark up pages with the same ease. For anyone wanting an e-reader that doubles as a digital notebook, the Elipsa 2E offers a more intuitive and versatile experience.
The Kobo Elipsa 2E is an ad-free 10.3-inch e-reader you can write on with the included stylus. It offers a whole host of useful features, like the ability to convert handwriting to typed text and a great selection of pen types.
Meanwhile, the Kobo Libra Colour is worth a look if you want something smaller but still feature-packed. Like the Kindle Colorsoft, it features a compact 7-inch color display that makes highlights, annotations, and comics pop compared to monochrome screens. Although the Colorsoft's hues are slightly more vibrant, the Libra Colour provides a pleasant, easy-on-the-eyes experience. It also includes physical page-turn buttons and stylus compatibility (sold separately), allowing you to mark up text or jot notes — features that the Colorsoft lacks despite costing more.
Kobo's main drawback is the lack of native Kindle book support, but it makes up for this with broader file format compatibility and support for direct borrowing from public libraries through OverDrive. Plus, if you don't mind a few extra steps, you can always convert Kindle books for use on Kobo devices.
The Libra Colour is one of the newest e-readers from Kobo and one of the first with color. With both OverDrive and Pocket support, it gives readers considerably more options than e-readers from bigger brands like Amazon.
Sign up for Verge Deals to get deals on products we've tested sent to your inbox weekly.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
AbbVie's Elahere Market Expected to Skyrocket to $6B by 2034 in Ovarian Cancer Treatment
AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, the 'Elahere Market Opportunities and Strategies to 2034' report was added to offering. It stated that the global market for Elahere, which is a treatment primarily for ovarian cancer, is anticipated to experience rapid growth and is projected to surge from nearly $502.56 million in 2024 to $6.07 billion by 2034 at a CAGR of 28.68% from 2029. AbbVie, through its acquisition of ImmunoGen, is currently the sole and dominant player in the Elahere market, holding a 100% market share in 2023. AbbVie completed its acquisition of ImmunoGen on February 12 in 2024, in a deal that was valued at ~$10.1 billion. The acquisition was made to support AbbVie's oncology pipeline, particularly with Elahere. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. Elahere is indicated for ovarian neoplasms, which constituted the largest segment by clinical indication and accounted for 85.44% or $429.38 million of the market in 2024. This segment is expected to remain the fastest-growing with a CAGR of 29.67% during the 2024-2029 period. North America was the largest regional market for Elahere in 2024, and accounted for 97.09% of the total, or $487.92 million. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
41 minutes ago
- Yahoo
5 Insightful Analyst Questions From Amentum's Q1 Earnings Call
Amentum's first quarter results were met with a negative market reaction, as its GAAP profit came in well below Wall Street's consensus despite revenue surpassing expectations. Management cited steady demand for its mission-focused solutions and highlighted progress on cost synergies from the recent integration with Jacobs. However, executives acknowledged that delays in government contract awards and ongoing transitions in joint venture structures weighed on growth. CEO John Heller pointed to recent wins in intelligence, nuclear, and naval sectors, but also recognized award timing and administrative shifts as significant factors shaping quarterly performance. Is now the time to buy AMTM? Find out in our full research report (it's free). Revenue: $3.49 billion vs analyst estimates of $3.42 billion (flat year on year, 2% beat) EPS (GAAP): $0.02 vs analyst expectations of $0.07 (71.4% miss) Adjusted EBITDA: $268 million vs analyst estimates of $255.9 million (7.7% margin, 4.7% beat) The company reconfirmed its revenue guidance for the full year of $14 billion at the midpoint EBITDA guidance for the full year is $1.08 billion at the midpoint, in line with analyst expectations Operating Margin: 3.5%, up from 2.1% in the same quarter last year Backlog: $44.8 billion at quarter end Market Capitalization: $5.85 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Tobey Sommer (Truist): asked about demand for nuclear solutions across geographies; CEO John Heller and COO Steve Arnette described expanding opportunities in the UK, Europe, and Australia, emphasizing long-term engagements in both gigawatt and small modular reactor projects. Andre Madrid (BTIG): inquired about the pace of contract awards amid industry-wide delays; CFO Travis Johnson confirmed timing impacts but cited strong year-to-date book-to-bill and robust pending award pipeline. Colin Canfield (Cantor Fitzgerald): questioned proceeds from the Rapid Solutions divestiture and implications for leverage; Johnson detailed after-tax proceeds and stressed the transaction's role in accelerating debt reduction. Ken Herbert (RBC Capital Markets): asked for specifics on headwinds affecting second half revenue growth, including joint venture transitions; Johnson explained that shifting joint ventures to unconsolidated status would reduce reported revenue but not free cash flow or EBITDA. Kristine Liwag (Morgan Stanley): pressed on risks from potential NASA budget cuts; Heller and Johnson indicated that space-related work for Artemis II and III is prioritized and they do not expect material impact to 2025 guidance. In the coming quarters, our team will track (1) the pace at which delayed government contract awards are resolved and converted into revenue, (2) the impact of the Rapid Solutions divestiture on debt and capital deployment flexibility, and (3) progress on cost synergy realization from the Jacobs integration. Additionally, we will watch for any shifts in government funding priorities that could affect Amentum's core defense, intelligence, and energy markets. Amentum currently trades at $24.63, up from $22.14 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
Stratasys's Q1 Earnings Call: Our Top 5 Analyst Questions
Stratasys' first quarter results were well received by the market, as the company delivered better-than-expected revenue and improved profit margins despite ongoing softness in capital equipment spending. Management attributed the quarter's performance to resilient consumables demand, disciplined cost controls, and the continued strength of its recurring revenue model. CEO Yoav Zeif highlighted that consumables sales rose 7% sequentially, reflecting high utilization rates across the installed base, while CFO Eitan Zamir noted that the impact of cost-saving initiatives launched last year has helped offset lower product sales. Is now the time to buy SSYS? Find out in our full research report (it's free). Revenue: $136 million vs analyst estimates of $134.6 million (5.6% year-on-year decline, 1.1% beat) Adjusted EPS: $0.04 vs analyst estimates of $0.02 ($0.03 beat) Adjusted EBITDA: $8.17 million vs analyst estimates of $6.79 million (6% margin, 20.3% beat) The company reconfirmed its revenue guidance for the full year of $577.5 million at the midpoint Management raised its full-year Adjusted EPS guidance to $0.33 at the midpoint, a 6.3% increase EBITDA guidance for the full year is $47 million at the midpoint, above analyst estimates of $44.64 million Operating Margin: -9.1%, up from -17% in the same quarter last year Market Capitalization: $939.6 million While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Brian Drab (William Blair) asked about the impact of U.S. tariffs on products imported from Israel. CEO Yoav Zeif said tariffs apply to the cost of goods but are 'not material' at current levels. Brian Drab (William Blair) inquired about macroeconomic assumptions behind the second-half forecast. CFO Eitan Zamir explained guidance assumes a slightly stronger second half, driven by seasonality and focus on EBITDA, but acknowledged ongoing uncertainty in capital spending. Danny Eggerichs (Craig-Hallum) questioned trends in consumables demand and customer utilization. Zamir reported higher utilization rates, with expectations for consumables revenue to grow year-over-year as manufacturing applications increase. Danny Eggerichs (Craig-Hallum) asked about near-term capital allocation after the Fortissimo investment. Zeif said the primary use will be for inorganic growth, with a focus on acquisitions that fit Stratasys' recurring revenue and manufacturing strategy. Troy Jensen (Cantor Fitzgerald) probed the decline in R&D spend and competition at the low end of the market. Zamir emphasized R&D was refocused, not cut, while Zeif reiterated that Stratasys is committed to industrial-grade, high-end markets rather than commoditized prototyping. In upcoming quarters, the StockStory team will be watching (1) the pace of sequential revenue growth, particularly in consumables and high-value manufacturing markets; (2) deployment of capital from the Fortissimo investment, including any announced acquisitions; and (3) the adoption and performance of new products like the Neo800 Plus and advanced materials in key verticals. Execution on cost controls and recurring revenue expansion will also be critical signposts. Stratasys currently trades at $11.20, up from $9.73 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
